DEFA14A: STAAR Surgical Go-Shop Ends Without Competing Bids

STAAR Surgical Company announced the expiration of its go-shop period for the Alcon merger, confirming no competing acquisition proposals were received.

Summary

• STAAR Surgical's go-shop period, related to its merger agreement with Alcon Inc., expired on December 6, 2025, at 11:59 p.m. Eastern Time.
• No competing acquisition proposals were received during the go-shop period.
• STAAR, assisted by financial advisor Citi, engaged with 21 third parties, including financial sponsors and strategic acquirers, to solicit alternative proposals.
• Only two of these 21 parties signed non-disclosure agreements and engaged in discussions with STAAR management, but neither submitted a competing acquisition proposal.
• The outcome discredits allegations by Broadwood Partners, L.P. regarding purported interest from other parties (Party A, B, and C), none of whom signed NDAs or submitted proposals.

Sentiment

Score: 7

Explanation: The filing confirms the merger is proceeding as planned without higher bids, validating the board's process and management's stance against activist investor claims. This reduces uncertainty regarding the merger's terms and likelihood of completion, which is generally positive for the existing merger agreement. However, the lack of competing bids could be seen as a missed opportunity for a higher valuation by some investors.

Positives

• The go-shop process validated the effectiveness of STAAR's Board's initial sale process and its decision to merge with Alcon.
• The outcome discredits allegations from Broadwood Partners, L.P., which had claimed significant external interest in acquiring STAAR.
• Management believes Alcon is the right buyer and that now is the right time to sell the business.

Negatives

• No higher bids or alternative acquisition proposals emerged during the go-shop period, indicating a lack of competitive interest beyond the Alcon offer.

Risks

• The occurrence of any event, change, or circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur.
• The failure to obtain approval of the proposed transaction from STAAR's stockholders.
• The failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all.
• Risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally.
• The ability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The company anticipates proceeding with the previously announced merger with Alcon Inc., following the validation of its initial sale process by the go-shop period. The completion of the transaction is subject to stockholder and regulatory approvals, and the satisfaction of other closing conditions.

Management Comments

• "The STAAR Board conducted a thoughtful sale process before the transaction was announced that was based on its extensive M&A experience, careful consideration of potential alternatives and its informed view of the ophthalmic space — experience and information that Broadwood does not possess." Stephen Farrell, CEO of STAAR.
• "The results of this go-shop confirm that the process that the Board pursued before approving the merger agreement — and its knowledge of STAAR’s business, risks and opportunities — produced the best buyer for STAAR." Stephen Farrell, CEO of STAAR.

Industry Context

STAAR Surgical is a global leader in phakic IOLs with its EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction. The proposed acquisition by Alcon, a major player in eye care, signifies further consolidation or strategic alignment within the ophthalmic surgery market, potentially strengthening Alcon's position in the premium vision correction segment.

Legal Proceedings

• The filing mentions the risk of "any legal proceedings that may be instituted against the Company related to the proposed transaction."

Stakeholder Impact

• Shareholders: Will vote on the proposed transaction. The stock price may decline significantly if the transaction is not consummated.
• Employees: Risk of disruption to management's attention and impact on ability to retain and hire key personnel due to the proposed transaction.
• Customers, Suppliers, and Others: Potential effect on maintaining relationships due to the proposed transaction.

Next Steps

• Stockholders are urged to read all relevant documents filed or to be filed with the SEC, including the Proxy Statement, before making any voting decision.
• Obtain stockholder approval for the proposed transaction.
• Obtain required regulatory approvals.
• Satisfy other closing conditions to complete the proposed transaction.

Key Dates

Recommendation

The filing confirms the go-shop period for the Alcon merger has expired without any superior offers, reinforcing the existing merger agreement. This reduces uncertainty around the deal's completion, which is generally positive for current shareholders expecting the merger to close at the agreed-upon terms. However, the absence of competing bids suggests the current offer might be the ceiling, limiting upside potential beyond the merger price. Investors should hold shares if they believe the merger will close as planned, but there's no new information to suggest a 'buy' for significant appreciation beyond the deal price, nor a 'sell' unless there's a belief the merger will fail.

Keywords

STAAR Surgical, Alcon, Merger, Go-Shop, Acquisition, Ophthalmic, EVO ICL, Vision Correction, SEC Filing, Proxy Statement